Sunitinib Malate
CAS No. 341031-54-7
Sunitinib Malate( SU11248 )
Catalog No. M14156 CAS No. 341031-54-7
Potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
50MG | 33 | In Stock |
|
100MG | 45 | In Stock |
|
200MG | 58 | In Stock |
|
500MG | 71 | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSunitinib Malate
-
NoteResearch use only, not for human use.
-
Brief DescriptionPotent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor.
-
DescriptionPotent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor. Also inhibits cellular receptor phosphorylation of FLT3, RET and CSF-1R. Exhibits antiangiogenic and antitumor activity in multiple xenograft models.
-
In VitroSunitinib Malate is also a good inhibitor of KIT and FLT-3. In RS4;11 cells (FLT3-WT), treatment with Sunitinib (SU11248) inhibits FLT3-WT phosphorylation in a dose-dependent manner with IC50 of approximately 250 nM. In MV4;11 cells that express FLT3-ITD, Sunitinib inhibits FLT3-ITD phosphorylation in a dose-dependent manner with an IC50 of 50 nM following a 2-hour treatment.In biochemical assays, Sunitinib (SU11248) exhibits competitive inhibition (with regard to ATP) against Flk-1 and PDGFRβ with Ki values of 9 nM and 8 nM, respectively. Sunitinib is also a competitive, albeit less potent, inhibitor of FGFR1 tyrosine kinase activity, with a Ki value of 0.83 μM. In addition to these three structurally related split kinase domain RTKs, the activity of Sunitinib has also been evaluated against a broad panel of additional tyrosine and serine/threonine kinases. In these biochemical assays, the IC50 values for Sunitinib are generally at least 10-fold higher than those for Flk-1 and PDGFR (e.g., IC50 values of: >10 μM for EGFR and Cdk2; 4 μM for Met; 2.4 μM for IGFR-1; 0.8 μM for Abl; and 0.6 μM for Src).
-
In VivoSunitinib Malate has very good oral bioavailability, is highly efficacious in a number of preclinical tumor models, and is well tolerated at efficacious doses. Sunitinib (80 mg/kg/day) inhibits the growth of established SF763T and Colo205 tumor xenografts in athymic mice. Sunitinib (SU11248) treatment effectively inhibits the growth of established tumor xenografts.
-
SynonymsSU11248
-
PathwayAngiogenesis
-
TargetFGFR
-
RecptorFGFR1| PDGFRβ| VEGFR2
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number341031-54-7
-
Formula Weight532.56
-
Molecular FormulaC26H33FN4O7
-
Purity>98% (HPLC)
-
SolubilityDMSO: 15 mg/mL (28.16 mM)
-
SMILESCCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C.C([C@@H](C(=O)O)O)C(=O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Sun L, et al. J Med Chem, 2003, 46(7), 1116-1119.
molnova catalog
related products
-
Sunitinib Malate
Potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor.
-
Derazantinib
Derazantinib (ARQ-087) is a novel potent, ATP competitive multi-kinase inhibitor with IC50 of FGFR1/2/3 with IC50 of 1.8-4.5 nM.
-
Sucralfate
Sucralfate is a cytoprotective agent, an oral gastrointestinal medication primarily indicated for the treatment of active duodenal ulcers.